Hemosiderosis in a patient on regular hemodialysis: treatment by desferrioxamine.
Hemosiderosis following regular administration of parenteral iron was observed in a patient receiving maintenance hemodialysis. Infusions of desferrioxamine in doses of 2,3 and 4 g each resulted in the removal of approximately 45 mg of iron during dialysis. Desferrioxamine 2 g was infused thrice weekly during dialysis for twelve months. Body iron stores, as judged by liver iron and serum ferritin concentrations, fell by about half. This agrees well with the result calculated from the amount of iron administered and the amount removed during dialysis.
D003676:Deferoxamine / Q000627:therapeutic use*; D005260:Female; D006486:Hemosiderosis / Q000188:drug therapy*; D006801:Humans; D007501:Iron / Q000009:adverse effects; D008875:Middle Aged; D006435:Renal Dialysis; D065227:Transfusion Reaction
D007501:Iron; D003676:Deferoxamine